October 21, 2016
CHICAGO — Visual acuity and anatomical improvements were achieved at all dose levels of nesvacumab combined with aflibercept in patients with diabetic macular edema or neovascular age-related macular degeneration, according to a study presented here.
David M. Brown
, MD, told colleagues at the American Academy of Ophthalmology meeting that observations in a preclinical model of chronic vascular leak showed that nesvacumab, an anti-Ang2 agent, combined with aflibercept, an anti-VEGF, increased duration of anti-leak action of aflibercept. The observation led to the hypothesis that the combined product could produce a greater therapeutic effect than inhibition of either VEGF or Ang2 alone.